Cation transport in mitochondria — The potassium cycle  by Garlid, Keith D.
ELSEVIER Biochimica et Biophysica Acta 1275 (1996) 123-126 
BB 
Biochi ~mic~a et Biophysica A~ta 
Cation transport in mitochondria - the potassium cycle 
Keith D. Garlid * 
Department ofChemistry, Bioehemisto,, and Molecular Biology, Oregon Graduate Institute of Science and Technology, P.O. Box 91000, Portland, OR 
97291-1000, USA 
Received 15 April 1996; accepted 16 April 1996 
Abstract 
The existence in mitochondria of separate, highly regulated pathways for K + influx and effiux strongly implies that mitochondrial 
volume is subject o regulation in vivo. Volume, in turn, has been shown to regulate activity of the electron transport chain. Thus, the 
mitochondrial K + cycle appears to play a key signalling role in regulating cellular bioenergetics, including the metabolic fate of fatty 
acids. Consistent with this role, the channel is inhibited by long-chain acyI-CoA esters and activated by GTP, and these ligands interact 
with sites that face the cytosol. The work to be summarized shows that KAT P channels from mitochondria nd plasma membranes are 
regulated by the same biochemical and pharmacological ligands. We hypothesize that the mitochondrial KAT P channel, like its 
counterparts in the plasma membrane, is heteromultimeric, consisting of a regulatory sulfonylurea receptor (mitoSUR) and an 
inward-rectifying K + channel (mitoKIR). 
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1. Introduction 
The mitochondrial K + cycle consists of electrophoretic 
K + uptake and electroneutral K + effiux across the inner 
membrane. The redox energy consumed by the cycle is the 
cost of regulating matrix volume [1]. Two transporters 
have been identified that catalyze K + transport, and both 
are highly regulated. Effiux is mediated by the K+/H + 
antiporter, whose existence was predicted by Mitchell [2] 
and first demonstrated nearly 20 years later [3]. A reconsti- 
tutively active K+/H + antiporter from liver and heart 
mitochondria has been identified as an 82 kDa inner 
membrane protein [4]. Influx is mediated by the mitochon- 
drial KAT P channel (mitOKATP). KAy P channels were iden- 
tified in plasma membranes of cardiac myocytes in 1984 
[5], and mitOKAT P were discovered in 1991. Inoue et al. [6] 
reported evidence from patch clamp studies of fused mito- 
plasts at the same time that we began describing reconsti- 
tution of a highly purified mitOKAT P. Although it pos- 
sesses unique properties, mitOKAT P is regulated by every 
ligand that regulates the plasma membrane KAT P channels 
(cellKATp); consequently, we infer that it belongs to the 
same gene family [7-10]. 
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A primary role of the regulated K+/H + antiporter is to 
compensate for unregulated K + leakage into the matrix, 
driven by the high voltages required for oxidative 
phosphorylation. Thus, the K+/H + antiporter is responsi- 
ble for volume homeostasis and is essential for maintain- 
ing vesicular integrity in the face of high ionic traffic 
across the inner membrane. 
The discovery of mitOKAv P has profound new implica- 
tions for the physiological role of the mitochondrial K + 
cycle, because the existence of a regulated K + influx 
pathway now permits volume regulation. For example, 
opening mitOKAT P will transiently shift the balance be- 
tween K + uniport and K+/H + antiport until the antiport 
catches up with the higher rate of K + influx. This will 
cause transient swelling and will result in a higher steady- 
state volume for as long as mitoKAv P remains open. Such 
a 'regulated interplay' between K + uniport and K+/H + 
antiport was correctly postulated many years ago by Brier- 
ley [11]. 
2. Materials and methods 
We have studied mitOKAT P reconstituted from beef 
heart, rat liver and brown adipose tissue mitochondria. We 
have also studied cel lKAT P reconstituted from beef heart 
sarcolemmal vesicles. MitOKAT P channel activity has been 
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quantitated using three techniques: electrical currents were 
measured in lipid bilayer membranes following fusion of 
vesicles containing purified mitOKAT P or celIKAT P. K + 
flUX in proteoliposomes was measured using steady-state 
spectroscopy of the fluorescent probe, PBFI. K + flux in 
intact mitochondria was measured using light scattering. 
These protocols are fully described in our publications and 
reviewed in Ref. [12]. 
3. Results and discussion 
3.1. Matrix volume is determined by net potassium flux 
When K + influx and effiux are out of balance, the 
resulting net K + flux will be accompanied by electroneu- 
tral flux of anions and osmotically obligated water [13]. 
Because matrix [K +] is about 180 mM, net K + transport 
will have little effect on the matrix concentration of K +, 
but it will have a profound effect on matrix volume. Any 
departure from zero net K + flux will cause a change of 
matrix volume. The importance of regulating K + flux to 
zero in the steady state is illustrated by the following: 
uncompensated K + uptake amounting to as little as 10% 
of H + pumping would double matrix volume within 1-2 
min [14]. The K+/H + antiporter is inhibited by matrix 
Mg 2+ (K~ -- 300 p~M) as well as by matrix protons, and 
the concentrations of these inhibitors decrease with uptake 
of K + salts, causing compensatory activation of K + effiux 
[131. 
3.2. Matrix volume regulates electron transport 
Fatty acids are the fuel for thermogenesis by brown 
adipose tissue mitochondria, nd their rate of oxidation is 
strictly controlled by matrix volume [15]. A thorough 
characterization of this phenomenon by Halestrap and 
coworkers [16] has led to the following conclusions: (1) 
Increased matrix volume, over the narrow range thought o 
obtain in vivo, greatly stimulates activity of the respiratory 
chain in both heart and liver mitochondria. [3-Oxidation of 
fatty acids is particularly sensitive to matrix volume. (2) 
The site of activation has been localized to membrane 
enzymes that feed electrons to ubiquinone. (3) Matrix 
volume changes have been observed in vivo during respi- 
ratory stimulation secondary to hormonal activation of 
liver [16] and brown adipose tissue [17]. (4) The molecular 
mechanism of volume activation is not known, but may 
involve a stretch receptor. 
These findings point to a signalling role for mitOKAT e 
in determining the metabolic fate of fatty acids and regu- 
lating cellular bioenergetics, ashas also been suggested by 
Halestrap [18] and Szewczyk et al. [19]. 
3.3. Basic properties of mitoKar p
K + flux through reconstituted mitOKAT P is highly se- 
lective for K ÷ and unaffected by Na-- or tetraethyl- 
ammonium. MitOKAT e is not voltage-gated, and the flux- 
voltage dependence is consistent with a channel containing 
a single energy well near the center of the membrane. The 
open channel conductance of mitOKAT P is about 16 pS in 
symmetric 150 mM KCl [10,20]. MitoKAT e activity has 
also been demonstrated in intact mitochondria [19,21 ]. To 
control for the unavoidable coexistence of K + diffusion, 
we compared the effects of ATP on fluxes of K + and 
TEA + . K + flux was inhibited by ATP to the level of 
TEA + flux. TEA + flux was unaffected by ATP [21]. 
3.4. Regulation of mitoKAv e by nucleotides and long-chain 
acyl-CoA esters 
MitOKAT P is subject o complex regulation by metabo- 
lites, in keeping with the hypothesis that this channel is 
involved in regulating electron transport. Following is a 
summary of K~/2 values for inhibitors and openers 
[7,9,10]: 
3.4.1. Inhibition of K + flux 
ATP: KI/2 = 22-30 IxM 
ADP: Ki/2 = 160-200 IxM 
Palmitoyl CoA: KI/2 = 0.25 txM 
Free Mg2+: Kl/2 = 80 ~M in 500 p~M ATP. 
Free Ca2+: K1/2 = 150 txM in 500 p~M ATP. 
3.4.2. Activation of inhibited K + flux 
500 IxM 500 p~M 1 p~M palm 
ATP ADP CoA 
GTP: KI/2 = 3-7 ixM 0.12 I~M 230 [zM 
GDP: Kl/2 = 140 IxM 3 ~zM not done 
ATP and ADP are mutually competitive inhibitors of 
K ÷ flux through mitOKAT P. Very careful studies demon- 
strate that the Hill slope for ATP inhibition is 1.0 and 
increases to 2 in the presence of 20 IxM GTP. K + flux 
through mitOKAT P is inhibited by palmitoyl CoA in both 
mitochondria and proteoliposomes. The Hill slope for pal- 
mitoyl CoA inhibition is 2. 
Inhibition of mitOKAT p exhibits an absolute requirement 
for divalent cations. ATP or palmitoyl CoA have no effect 
in the absence of Mg 2÷, and Mg 2+ has no effect in the 
absence of ATP or palmitoyl CoA. Mg 2+ also prevents 
glyburide inhibition. Since glyburide and palmitoyl CoA 
are not Mg 2+ chelators, these findings indicate that Mg 2÷ 
interacts independently with mitoK ATe and not as a MgATP 
complex. 
The high affinity of mitoKAx P for ATP raised the 
conundrum of how this channel can be opened under 
physiological conditions. We hypothesized that endoge- 
nous activators overcome the high affinity for ATP, and 
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we have now confirmed this hypothesis by showing that 
guanine nucleotides reverse the inhibition by ATP, ADP or 
palmitoyl CoA in both mitochondria and proteoliposomes. 
Guanine nucleotides are competitive with ATP. GTP 
appears to react with a high affinity (0.2 I~M) and a low 
affinity (15-20 I.zM) site, whereas GDP appears to react 
with two low affinity sites (20 IxM). ATP is unable to 
inhibit in the presence of physiological GTP concentra- 
tions; for example, 20 ixM GTP increased the KI/2 for 
ATP inhibition from 21 I~M to 6 mM. On the other hand, 
the Kl/2 for GTP activation of palmitoyl CoA inhibition 
is in the physiological range. Our thinking is that ATP 
does not regulate mitoKAv P at all, because the nucleotide- 
binding sites are always occupied by the high affinity 
ligands. We suggest that the open/closed state of the 
channel is determined in vivo by the relative occupancy of 
the sites by GTP or long-chain acyl CoA esters. We 
speculate that the 2 binding sites correspond to the nu- 
cleotide binding folds on mitoSUR. 
3.5. Orientation of mitoKAr e in the inner membrane 
In order to understand the signalling role of mitOKAx P 
in cell bioenergetics, it is necessary to know where its 
regulatory sites are located. Do they face the matrix, as 
suggested by Inoue [6] and Halestrap [18], or do they face 
the cytosol? Do they all coexist on the same pole of the 
protein? Experiments with proteoliposomes, mitochondria 
and BLM provided an unambiguous answers to these 
questions: the mitoKav e regulatory sites for Mg 2+, ATP, 
GTP and palmitoyl CoA face the cytosol [10]. 
3.6. MitOKAT e is an intracellular eceptor for K + chan- 
nel openers 
K + channel openers (KCOs) activate ATP-inhibited 
KAy P channels and exhibit a rich and clinically important 
pharmacology [22]. It is important o establish whether 
these drugs, which distribute throughout the cell, also act 
on mitochondrial KAy P channels in their therapeutic range. 
We have found that KCOs reverse inhibition by ATP, 
ADP, palmitoyl CoA and glyburide, and that the K1/2 
values (below) are well within the range observed with 
celIKAT P from various tissues [22]. Similar results were 
obtained in intact mitochondria. 
KCOs reverse inhibition 
by 500 ~M ATP: 
Cromakalim: K~/2 = 1 IxM 
Diazoxide: K1/2 = 0.4 txM 
EMD 60480: Kj/2 = 1 nM 
EMD 57970: Kj/2 = 6 nM 
channel - they have no effect on uninhibited K + flux, 
which is also characteristic of cellKAT P. Our finding that 
KCOs in the therapeutic range do not open the uninhibited 
channel is consistent with the results of Szewczyk et al. 
[23], who did not include Mg 2÷ and ATP in the assay 
medium used for their studies. 
Recognition of mitOKAx P as an intracellular receptor for 
KCOs adds a new dimension to KCO pharmacology, 
which has been focused exclusively on plasma membrane 
KAT P channels. A particularly exciting development in 
KCO pharmacology is the finding by Grover and col- 
leagues [24] that KCOs are cardioprotective during experi- 
mental ischemia. KCO-treated hearts maintain higher ATP 
levels and exhibit reduced infarct size and enhanced post- 
ischemic recovery upon reperfusion. All of these effects 
are blocked by glyburide. These pharmacological effects 
point to a role of KAT P channels in myocardial protection; 
but the receptor for these effects has not been identified, 
and a mitochondrial site of action cannot be excluded [25]. 
We have now demonstrated that cardiac mitOKAv P and 
celIKAT P can be distinguished pharmacologically [8]. We 
compared drug sensitivities of cardiac mitoKAr P and 
cellKAT P reconstituted from beef heart mitochondria nd 
sarcolemma, respectively. MitOKAT p and cellKAT P exhibit 
similar sensitivities to cromakalim and other benzopyran 
derivatives; however, they differ strikingly in their sensi- 
tivity to diazoxide. Cardiac mitOKAv P is 2000 times more 
sensitive to diazoxide than cardiac cellKAv P. In the is- 
chemic model, diazoxide was cardioprotective over the 
same dose range as cromakalim and at doses that had no 
effect on cellKAv P (G. Grover, personal communication). 
These findings raise the strong and exciting possibility that 
mitOKAv P is the receptor for the cardioprotective effects of 
KCOs. 
3. 7. MitOKAT e is an intracellular drug receptor for gly- 
buride 
Glyburide is an antidiabetic sulfonylurea that triggers 
insulin release from pancreatic 13-cells, presumably by 
inhibiting 13-cellKAT P [22]. Glyburide is a potent inhibitor 
of K + flux through reconstituted mitOKAv P, with KI /2  = 
60 nM in the absence of Mg 2+ [7]. We were unable to 
detect inhibition of K + flux in intact mitochondria [21], 
and we have observed profound inhibition of TEA + flux at 
the high doses used by Belyaeva et al. [26]. We have 
recently reinvestigated this phenomenon and found that 
glyburide is very potent in mitochondria (K~/2 = 24 nM) 
when the assay is preceded by preincubation with the drug. 
These preliminary results suggest hat the kinetics of gly- 
buride binding are slow, but this remains to be confirmed. 
(The EMD drugs are experimental benzopyranyl deriva- 
tives (cromakalim analogues) from E. Merck and Co.) 
It is important to stress that KCOs cannot open an open 
3.8. ls mitoKMp a heteromultimeric complex? 
Each of the metabolic and pharmacological ligands that 
modify cellKAT P also modify mitoKavp, and they do so in 
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the same dose range. MitOKAT P is distinctive in its abso- 
lute requirement for divalent cations for nucleotide inhibi- 
tion. A second distinction is found in the effects of ADP 
and long-chain acyl-CoA esters. Most cellKgT P are opened 
by MgADP, and Corkey and coworkers [27] have recently 
demonstrated that the 13-cellKAT p is opened by oleoyl CoA 
in the 200-300 nM range. The parallel, albeit opposite, 
effects of ADP and long-chain acyl-CoA esters are consis- 
tent with the fact that the CoA moiety is an ADP analogue. 
These distinctions must reside in the communication 
between the nucleotide regulatory domain and the trans- 
port domain. This communication has been clarified by the 
recent achievements of the Bryans' laboratory [28-30], 
who have succeeded in the molecular cloning of [3- 
ceI1KAT P. Their work shows that celIKAT P consists of two 
separate proteins, a sulfonylurea receptor (SUR) and a 
separate inward-rectifying K ÷ channel (KIR). SUR is a 
member of the ATP-binding cassette (ABC) family and 
contains two nucleotide-binding folds. When SUR was 
co-expressed with Kir6.2, full KAT P channel activity was 
observed, including regulation by ATP, sulfonylureas, and 
diazoxide. 
Preliminary studies have led us to a working hypothesis 
[10] that mitOKgT p is also a heteromultimer consisting of 
an inward rectifying K + channel, mitoKIR, and a sulfony- 
lurea receptor, mitoSUR. This hypothesis is under active 
investigation i our laboratory. 
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